Go to full publication
Editorial: Extracellular Matrix Biomarkers Illuminate the Architecture of Portal Hypertension in End-Stage Liver Disease-Authors’ Reply.
December 21, 2025
Aliment Pharmacol Ther
- Home
-
Publications
Publications
Active filters
Add filters (0)
18 results
MetALD: Diagnosis and Prognosis With Non-Invasive Tests.
November 1, 2025
Aliment Pharmacol Ther
Abstract BACKGROUND Non-invasive tests (NITs) are central to diagnosing and stratifying risk in steatotic liver disease (SLD). However, it remains unclear whether guideline-recommended NIT cut-offs apply to metabolic and alcohol-related liver disease (MetALD). AIM Evaluate the diagnostic and prognostic performance of five NITs in patients with MetALD. METHODS Single-centre study with 423 SLD patients, of […]
MetALD: Diagnosis and Prognosis With Non-Invasive Tests.
November 1, 2025
Aliment Pharmacol Ther
Abstract BACKGROUND Non-invasive tests (NITs) are central to diagnosing and stratifying risk in steatotic liver disease (SLD). However, it remains unclear whether guideline-recommended NIT cut-offs apply to metabolic and alcohol-related liver disease (MetALD). AIM Evaluate the diagnostic and prognostic performance of five NITs in patients with MetALD. METHODS Single-centre study with 423 SLD patients, of […]
MetALD: Diagnosis and Prognosis With Non-Invasive Tests.
November 1, 2025
Aliment Pharmacol Ther
Abstract BACKGROUND Non-invasive tests (NITs) are central to diagnosing and stratifying risk in steatotic liver disease (SLD). However, it remains unclear whether guideline-recommended NIT cut-offs apply to metabolic and alcohol-related liver disease (MetALD). AIM Evaluate the diagnostic and prognostic performance of five NITs in patients with MetALD. METHODS Single-centre study with 423 SLD patients, of […]
MetALD: Diagnosis and Prognosis With Non-Invasive Tests.
November 1, 2025
Aliment Pharmacol Ther
Abstract BACKGROUND Non-invasive tests (NITs) are central to diagnosing and stratifying risk in steatotic liver disease (SLD). However, it remains unclear whether guideline-recommended NIT cut-offs apply to metabolic and alcohol-related liver disease (MetALD). AIM Evaluate the diagnostic and prognostic performance of five NITs in patients with MetALD. METHODS Single-centre study with 423 SLD patients, of […]
MetALD: Diagnosis and Prognosis With Non-Invasive Tests.
November 1, 2025
Aliment Pharmacol Ther
Abstract BACKGROUND Non-invasive tests (NITs) are central to diagnosing and stratifying risk in steatotic liver disease (SLD). However, it remains unclear whether guideline-recommended NIT cut-offs apply to metabolic and alcohol-related liver disease (MetALD). AIM Evaluate the diagnostic and prognostic performance of five NITs in patients with MetALD. METHODS Single-centre study with 423 SLD patients, of […]
Biomarkers of Extracellular Matrix Remodelling Are Linked to Severity and Outcome of Advanced Chronic Liver Disease.
October 12, 2025
Aliment Pharmacol Ther
Abstract BACKGROUND Extracellular matrix (ECM) remodelling in advanced chronic liver disease (ACLD) is characterised by hepatic fibrosis and (sinusoidal) basement membrane development contributing to portal hypertension (PH) and clinical complications. METHODS Patients with stable ACLD (n = 232) undergoing hepatic venous pressure gradient (HVPG) measurement were included. Blood biomarkers reflecting fibrosis formation (PRO-C3, PRO-C6, PRO-C4 and PRO-C18L) […]
A prospective pilot study of a gluten-free diet for primary sclerosing cholangitis and associated colitis.
January 1, 2023
Aliment Pharmacol Ther
Abstract BACKGROUND Primary sclerosing cholangitis (PSC) is a progressive bile duct disease associated with inflammatory bowel disease (PSC-IBD). AIM To investigate whether patients with PSC-IBD benefit from a gluten-free and amylase trypsin inhibitor (ATI)-free diet (GFD). METHODS We performed a prospective clinical pilot study administering an eight-week GFD. The primary outcomes were colonic inflammation assessed […]
Serological biomarkers of type I, III and IV collagen turnover are associated with the presence and future progression of stricturing and penetrating Crohn’s disease.
August 1, 2022
Aliment Pharmacol Ther
Abstract BACKGROUND Increased collagen remodelling is a key pathophysiological component underlying intestinal stricture and fistula development in Crohn’s disease (CD). AIMS To investigate associations between serological biomarkers of collagen turnover and disease behaviour according to the Montreal classification in patients with CD. METHODS Serological biomarkers of type III/IV collagen formation (PRO-C3, PRO-C4) and matrix metalloproteinase […]
Editorial: biomarkers for alcohol-related liver fibrosis-almost there? Authors’ reply.
December 1, 2021
Aliment Pharmacol Ther
Go to full publication
